Cargando…
Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease
To assess the efficacy and safety of eltrombopag in connective tissue disease (CTD)-immune thrombocytopenia (ITP), we conducted this single-center retrospective observational study, including patients with refractory CTD-ITP who were treated with eltrombopag between January 2018 and August 2019. The...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943759/ https://www.ncbi.nlm.nih.gov/pubmed/33750817 http://dx.doi.org/10.1038/s41598-021-84493-2 |